Pei‐Ran Ho

2.4k total citations
45 papers, 1.3k citations indexed

About

Pei‐Ran Ho is a scholar working on Oncology, Pathology and Forensic Medicine and Orthopedics and Sports Medicine. According to data from OpenAlex, Pei‐Ran Ho has authored 45 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Pathology and Forensic Medicine and 9 papers in Orthopedics and Sports Medicine. Recurrent topics in Pei‐Ran Ho's work include Polyomavirus and related diseases (22 papers), Multiple Sclerosis Research Studies (19 papers) and Bone health and treatments (9 papers). Pei‐Ran Ho is often cited by papers focused on Polyomavirus and related diseases (22 papers), Multiple Sclerosis Research Studies (19 papers) and Bone health and treatments (9 papers). Pei‐Ran Ho collaborates with scholars based in United States, Germany and Italy. Pei‐Ran Ho's co-authors include Nolan Campbell, Ih Chang, Sandra Richman, Harold Koendgen, Jacques P. Brown, Joseph M. Lane, Rachel B. Wagman, Rachna Kasliwal, Andrea Wang and Akhila Balasubramanian and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Neurology and Journal of Bone and Joint Surgery.

In The Last Decade

Pei‐Ran Ho

43 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pei‐Ran Ho United States	18	727	487	473	280	245	45	1.3k
Jung Ryul Kim South Korea	23	431 0.6×	188 0.4×	197 0.4×	466 1.7×	662 2.7×	92	1.7k
P.S. Mortimer United Kingdom	24	1.2k 1.7×	202 0.4×	57 0.1×	200 0.7×	752 3.1×	45	1.6k
Céline Bazille France	20	309 0.4×	88 0.2×	42 0.1×	449 1.6×	187 0.8×	54	1.2k
Stephanie Finzel Germany	25	110 0.2×	96 0.2×	333 0.7×	288 1.0×	347 1.4×	86	1.9k
Toru Fujimoto Japan	13	85 0.1×	169 0.3×	129 0.3×	233 0.8×	266 1.1×	38	814
Howard A. Chansky United States	23	133 0.2×	94 0.2×	55 0.1×	916 3.3×	428 1.7×	46	1.8k
A. Karim Ahmed United States	19	55 0.1×	310 0.6×	54 0.1×	174 0.6×	516 2.1×	48	942
Taichi Saito Japan	15	76 0.1×	106 0.2×	110 0.2×	169 0.6×	376 1.5×	60	740
José Ramón Ricoy Spain	20	102 0.1×	79 0.2×	32 0.1×	330 1.2×	151 0.6×	50	1.3k

Countries citing papers authored by Pei‐Ran Ho

Since Specialization

Citations

This map shows the geographic impact of Pei‐Ran Ho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pei‐Ran Ho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pei‐Ran Ho more than expected).

Fields of papers citing papers by Pei‐Ran Ho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pei‐Ran Ho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pei‐Ran Ho. The network helps show where Pei‐Ran Ho may publish in the future.

Co-authorship network of co-authors of Pei‐Ran Ho

This figure shows the co-authorship network connecting the top 25 collaborators of Pei‐Ran Ho. A scholar is included among the top collaborators of Pei‐Ran Ho based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pei‐Ran Ho. Pei‐Ran Ho is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Butzkueven, Helmut, Stephanie Licata, Douglas Jeffery, et al.. (2020). Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. BMJ Open. 10(10). e038861–e038861. 17 indexed citations

Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2020). Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database (1988). Neurology. 94(15_supplement). 2 indexed citations

Butzkueven, Helmut, Ludwig Kappos, Heinz Wiendl, et al.. (2020). Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology Neurosurgery & Psychiatry. 91(6). 660–668. 99 indexed citations

Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 93(15). e1452–e1462. 116 indexed citations

Campbell, Nolan, Jeffrey A. Cohen, Heinz Wiendl, et al.. (2019). Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study (P3.2-095). Neurology. 92(15_supplement).

Foley, John, Karleyton C. Evans, Pei‐Ran Ho, et al.. (2019). The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. Multiple Sclerosis and Related Disorders. 39. 101863–101863. 25 indexed citations

Ryerson, Lana Zhovtis, John Foley, Ih Chang, et al.. (2019). Reduced risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab extended interval dosing (EID): updated analysis of the TOUCH® Prescribing Program database (S26.006). Neurology. 92(15_supplement). 2 indexed citations

Ho, Pei‐Ran, et al.. (2017). Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. The Lancet Neurology. 16(11). 925–933. 209 indexed citations

Butzkueven, Helmut, Ludwig Kappos, María Trojano, et al.. (2016). Real-World Safety and Efficacy of Natalizumab after Switching from Other Disease-Modifying Therapies (DMTs): Data from the Tysabri® Observational Program (TOP) (P2.069). Neurology. 86(16_supplement). 2 indexed citations

10.

Brown, Jacques P., Christian Roux, Pei‐Ran Ho, et al.. (2014). Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporosis International. 25(7). 1953–61. 44 indexed citations

11.

Palacios, Santiago, Irene Agodoa, Sydney Lou Bonnick, et al.. (2014). Treatment Satisfaction in Postmenopausal Women Suboptimally Adherent to Bisphosphonates Who Transitioned to Denosumab Compared With Risedronate or Ibandronate. The Journal of Clinical Endocrinology & Metabolism. 100(3). E487–E492. 17 indexed citations

12.

Roux, C., Lorenz C. Hofbauer, Pei‐Ran Ho, et al.. (2013). Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. Bone. 58. 48–54. 119 indexed citations

13.

Adami, Silvano, Cesar Libanati, Steven Boonen, et al.. (2012). Denosumab Treatment in Postmenopausal Women with Osteoporosis Does Not Interfere with Fracture-Healing. Journal of Bone and Joint Surgery. 94(23). 2113–2119. 85 indexed citations

14.

Brown, Jacques P., Christian Roux, Ove Törring, et al.. (2012). Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. Journal of Bone and Mineral Research. 28(4). 746–752. 108 indexed citations

15.

Terris, David J., Elbert T. Cheng, David S. Utley, et al.. (1999). Functional recovery following nerve injury and repair by silicon tubulization: comparison of laminin-fibronectin, dialyzed plasma, collagen gel, and phosphate buffered solution. Auris Nasus Larynx. 26(2). 117–122. 21 indexed citations

16.

Zhang, Feng, et al.. (1998). Results of termino-lateral neurorrhaphy to original and adjacent nerves. Microsurgery. 18(4). 276–281. 25 indexed citations

17.

Ho, Pei‐Ran, et al.. (1998). Repair With Collagen Tubules Linked With Brain-Derived Neurotrophic Factor and Ciliary Neurotrophic Factor in a Rat Sciatic Nerve Injury Model. Archives of Otolaryngology - Head and Neck Surgery. 124(7). 761–761. 51 indexed citations

18.

Cheng, Elbert T., David S. Utley, Pei‐Ran Ho, et al.. (1998). Functional recovery of transected nerves treated with systemic BDNF and CNTF. Microsurgery. 18(1). 35–41. 18 indexed citations

19.

Zhang, Feng, et al.. (1996). Effect of vein grafting on the survival of microvascularly transplanted muscle flaps. Microsurgery. 17(9). 512–516. 14 indexed citations

20.

Ho, Pei‐Ran, et al.. (1996). Gluteal Infarction as a Complication of Aortofemoral Bypass Grafting. Annals of Plastic Surgery. 37(6). 645–649. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact